Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.

Phase 3

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Pregabalin